Patients with rare blood disorders who receive targeted oral therapy report better symptoms and a reduction in disease burden.

Published Date: 13 Dec 2023

Results showed that bezuclastinib, a targeted therapy, was safe, quickly decreased markers of disease burden, and improved symptoms for patients with nonadvanced system mastocytosis, a rare blood disorder.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot